期刊
ONCOGENE
卷 32, 期 11, 页码 1341-1350出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2012.164
关键词
TRAIL; pro-apoptotic receptor agonists; apoptosis; TRAIL resistance; clinical trials
资金
- NIH [CA124545]
- Department of Defense (DOD) [BC093627]
- Swedish Research Council [2009-618]
- DOD Ovarian Cancer Idea Award [OC06143]
- Department of Obstetrics and Gynecology Academic Enrichment Fund (AEF), University of Colorado-Denver Hospitals
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and agonistic antibodies against TRAIL death receptors (DR) kill tumor cells while causing virtually no damage to normal cells. Several novel drugs targeting TRAIL receptors are currently in clinical trials. However, TRAIL resistance is a common obstacle in TRAIL-based therapy and limits the efficiency of these drugs. In this review article we discuss different mechanisms of TRAIL resistance, and how they can be predicted and therapeutically circumvented. In addition, we provide a brief overview of all TRAIL-based clinical trials conducted so far. It is apparent that although the effects of TRAIL therapy are disappointingly modest overall, a small subset of patients responds very well to TRAIL. We argue that the true potential of targeting TRAIL DRs in cancer can only be reached when we find efficient ways to select for those patients that are most likely to benefit from the treatment. To achieve this, it is crucial to identify biomarkers that can help us predict TRAIL sensitivity. Oncogene (2013) 32, 1341-1350; doi:10.1038/onc.2012.164; published online 14 May 2012
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据